ArticleArthroplasty today2025
Extensive Femoral Bone Loss Following Two-Stage Periprosthetic Joint Infection Treatment: Persistent Challenges in Proximal Femoral Replacement.
Article in Arthroplasty today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proximal femoral replacement (PFR) has gained popularity in nononcological reconstruction surgeries over recent decades. However, there is sparse literature on its application in extensive bone defects following 2-stage revision treatment for periprosthetic joint infection (PJI). This study retrospectively evaluates the clinical and functional outcomes, complication rates, and prosthesis survivorship in patients undergoing PFR surgery for severe bone defects due to 2-stage PJI treatment. Method: This single-center retrospective study analyzed patients who underwent PFR as part of a 2-stage treatment for hip arthroplasty-related PJI between 2010 and 2020. All patients had extensive proximal femoral bone loss (Paprosky type 3B and 4) before the PFR surgery. Inclusion required a minimum follow-up period of 24 months. Functional outcomes were evaluated using the Musculoskeletal Tumor Society Score (MSTS), while PFR prosthesis failure was classified according to Henderson's Classification. Combined PFR and acetabular prosthesis survival was determined using Kaplan-Meier survival curves. Results: Thirty-four patients (21 women and 13 men, average age 72.9) were included in the study. The mean follow-up was 75 months (range: 24-132). Pre-PFR surgeries averaged 3.88 per patient (range: 2-13). Mechanical complications were present in 7 patients (20.6%), nonmechanical complications in 8 (23.5%), and 2 patients (5.9%) had both. The mean MSTS score was 66.74%. The all-cause complication-free survival rate was 80% in the second year and decreased to 52% by the fifth year. The all-cause revision-free rate was 73 % in the second year and decreased to 47% by the fifth year. Conclusions: PFR is effective for limb salvage in complex cases but comes with high mechanical and non-mechanical complications and moderate to poor survival rates. While larger femoral heads and constrained liners help reduce dislocation, infection remains a significant issue. The gap between high MSTS scores and difficulties in daily activities signals a need for improved functional assessment tools. These findings highlight the persistent challenges in managing PJIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.